



## Taysha Gene Therapies to Participate in Upcoming August Investor Conferences

*BTIG Biotechnology Conference on August 8, 2022 at 1:00 pm ET*

*2022 Webbush PacGrow Healthcare Virtual Conference on August 10, 2022 at 9:45 am ET*

DALLAS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in panel discussions at the BTIG Biotechnology Conference on August 8<sup>th</sup> and the 2022 Webbush PacGrow Healthcare Virtual Conference on August 10<sup>th</sup>.

A webcast of the panels will be available in the "Events & Media" section of the Taysha corporate website at <https://ir.tayshagtx.com/news-events/events-presentations>. Archived versions of the webcast will be available on the website for 90 days.

### Conference Details:

Event: *BTIG Biotechnology Conference*  
Topic: AAV Gene Therapies for CNS Disorders: Challenges and Opportunities  
Date: Monday August 8  
Time: 1:00 pm ET  
Format: Panel discussion  
Participant: Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of Research and Development

Event: *2022 Webbush PacGrow Healthcare Virtual Conference*  
Topic: UltraOrphan: When You're One in a Million  
Date: Wednesday, August 10  
Time: 9:45 am ET  
Format: Panel discussion  
Participant: RA Session II, President, Founder and Chief Executive Officer

### About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team's proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients' lives. More information is available at [www.tayshagtx.com](http://www.tayshagtx.com).

### Company Contact:

Kimberly Lee, D.O.  
Chief Corporate Affairs Officer  
Taysha Gene Therapies  
[klee@tayshagtx.com](mailto:klee@tayshagtx.com)

### Media Contact:

Carolyn Hawley  
Evoke Canale  
[carolyn.hawley@evokegroup.com](mailto:carolyn.hawley@evokegroup.com)

